Skip to search formSkip to main contentSkip to account menu
Romiplostim or standard of care in patients with immune thrombocytopenia.
TLDR
Patients treated with romiplostim had a higher rate of a platelet response, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions, and a higher quality of life than patients treated with the standard of care.
View on PubMed
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
TLDR
PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC, and showed an acceptable safety profile and clinical activity in a subset of patients with MBC.
View on Springer
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon…
TLDR
In this large prospective trial, molecular tumor profiling predicted a tissue of origin in most patients with CUP and compares favorably with previous results using empiric CUP regimens.
View on PubMed
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
View on PubMed
Monoclonal gammopathy of undetermined significance: a consensus statement
TLDR
The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.
View on Wiley
Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
View on PubMed
Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
TLDR
Serum BCMA levels were found to be higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma patients than in healthy subjects, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib.
View on Wiley
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
TLDR
Brentuximab vedotin monotherapy may provide a frontline treatment option for older patients who cannot tolerate conventional combination chemotherapy for Hodgkin lymphoma, and preliminary data showed no substantial age-related changes in brentuxo-vedotin pharmacokinetics.
View on PubMed
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly…
TLDR
A single subcutaneous APF530 injection offers a convenient alternative to palonosetron for preventing acute and delayed CINV after MEC or HEC.
View on Springer
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized,…
TLDR
The GTDS provides effective, well-tolerated control of CINV associated with moderately or highly emetogenic multi-day chemotherapy and offers a convenient alternative route for delivering granisetron for up to 7 days that is as effective as oral granisettron.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License